NORML

New Jersey Governor Chris Christie recently made public statements calling the notion of regulating adult marijuana use “beyond stupidity.”

Yet, according to a 2015 Rutgers-Eagleton poll, nearly six in ten New Jersey adults support “legalizing, taxing, and regulating marijuana for adults 21 and over.” Similar percentages of voters through the country also endorse legalization.

That’s because the majority of Americans realize that the ongoing enforcement of marijuana prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, and disproportionately impacts young people and communities of color. It makes no sense from a public health perspective, a fiscal perspective, or a moral perspective to perpetuate the prosecution and stigmatization of those adults who choose to responsibly consume a substance that is safer than either alcohol or tobacco. 

In truth, America’s real-world experiment with regulating marijuana has been a success. Thirty states, including New Jersey, now regulate the plant’s therapeutic use and eight states authorize its use and sale to all adults. These policy changes are not associated with increased marijuana use or access by adolescents or with adverse effects on traffic safety or in the workplace. Marijuana regulations are also associated with less opioid abuse and mortality. In jurisdictions where this retail market is taxed, revenue from marijuana sales has greatly exceeded initial expectations.

Help us educate the Governor and his staff to the facts on marijuana. Enter your information below to urge Gov. Christie to support legalization. 

Update: A. 7006 was approved by the Senate on June 20 by a vote of 50 to 13. The measure now awaits action from the Governor.
Update: Companion legislation, S. 5629 has passed the Senate Health Committee and now heads to the full Senate for consideration.
Update: A 7006 was referred to committee in the Senate.
Update: Governor Andrew Cuomo says that he is open to expanding the state’s medical cannabis program to include patients with PTSD.

Update: The New York Assembly passed A 7006 on May 2. The bill now awaits action by the Senate. 
Legislation is moving forward, A. 7006, to allow patients with post-traumatic stress eligible for medical cannabis therapy.
New York is one of the only states with a medical marijuana program that does not allow patients with PTSD access to medical cannabis.
Please use the pre-written letter below to urge your lawmakers to support this effort. 

Legislation is pending to expedite the retail sale of marijuana products to those over the age of 21.

LD 1448 and LD 1491 would permit licensed medical cannabis dispensaries the opportunity to “sell limited marijuana retail products to a person who is 21 years of age or older.”

A majority of voters in November approved an initiated measure to permit the possession, production, and retail sale of marijuana and marijuana-infused products. However, emergency legislation signed into law in January delays the implementation of regulations overseeing the commercial production and retail sale of marijuana until at least February 1, 2018.

Passage of these measures would allow dispensaries to engage in marijuana sales ahead of this date.

Please use the pre-written letter below to urge lawmakers to move forward with LD 1448/LD 1491.

Legislation was signed into law that permits registered medical cannabis patients to legally use marijuana while on bond in a criminal case.

Senate Bill 17 states, “[T]he court shall not require as a condition of any bond that [s] person … with a valid registry identification card … abstain from the use of medical marijuana.” You can read the full text of the new law here.

Existing law permits qualified patients to engage in cannabis therapy while probation, but only in circumstances where a judge does not object to it. 

The new law takes effect on August 9, 2017.

Follow Colorado NORML, Denver NORML, and Southern Colorado NORML. 

Update: The Assembly Housing and Community Development Committee voted in favor of AB 62 by a vote of 7-0 on April 27 and now heads to the full Assembly. 
Legislation introduced by Assemblyman Jim Wood, AB 62, would ban smoking and vaping of tobacco, cannabis, and other medicinal herbs in public housing. 
Cal NORML opposes the bill on the grounds that it bans cannabis as well as tobacco, making it impossible for medical cannabis patients to inhale their medicine legally. Unlike cannabis users, tobacco smokers are allowed to smoke openly in public, where use of cannabis is banned under Prop 64. There is no reason to think that cannabis poses the same second-hand exposure risks as tobacco.
Other opponents of AB 62 include the ACLU, the Western Center on Law and Poverty, and California Rural Legal Assistance Foundation. They argue against the inclusion of electronic cigarettes for reasons including the increased the risk of eviction and therefore homelessness among public housing residents.
Federal rules already prohibit smoking in public housing, but do not include e-cigarettes. This is because there is no evidence that e-cigs pose a significant public health hazard, as they effectively eliminate harmful second-hand smoke toxins. 
Meanwhile, NORML continues to hear from seriously ill people thoughout the country who are being evicted for smoking or vaping medical cannabis. Californian patients deserve to be able to consume their medicine.
Enter your information below to send a message to your state lawmakers urging them to oppose AB 62. 

Update: HR 2273 and S. 1008 were referred to committees in their respective chambers.
A bipartisan coalition of legislators has introduced HR 2273 to legalize the therapeutic use of cannabidiol (CBD).
Senate companion legislation, S. 1008, is also pending before lawmakers.

The bill amends the US Controlled Substances Act to exclude CBD and CBD-rich cannabis plants from the federal definition of marijuana. Under the present definition, all of the organic cannabinoids in the plant are classified as Schedule I controlled substances.

Cannabidiol is non-intoxicating and clinical studies have determined it to be safe and well-tolerated in human subjects. The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, acknowledges that CBD is “a safe drug with no addictive effects.” Many patients now utilize CBD, primarily for its anti-convulsant effects.

Seventeen states now acknowledge the therapeutic use of CBD by statute. However, because CBD products and high CBD-bearing remain illegal federally, patients typically lack a consistent, high-quality legal, in-state supply source for this medicine. 

Please use the pre-written letter below to urge lawmakers to take action on HR 2237.